LOS ALTOS, CA – March 11, 2026 – Wordly, the pioneer and leader in live AI translation and captions, today announced the launch of the Wordly Subtitles Application, a new tool that allows production teams to easily overlay live captions and subtitles directly onto presentations, video streams, and other content at conferences, hybrid events, and enterprise broadcasts. 

“Captions have become a standard part of how audiences consume content today,” said Lakshman Rathnam, Founder and CEO of Wordly. “An estimated 85% of viewers worldwide use captions or subtitles at some point while watching content. Whether it’s a TV show, livestream, or a presentation on the main stage at a conference, audiences increasingly expect to be able to follow along visually.” 

Purpose-built for AV professionals, the Wordly Subtitles App extends real-time AI captioning and translation directly into production environments. Instead of just displaying captions on a side monitor or browser window, the app generates high-quality overlays that can be projected on main stage screens or embedded into streams, helping audiences follow content clearly whether they are in the room or watching remotely. 

The Wordly Subtitles App connects to an active Wordly session and renders real-time captions in multiple display formats optimized for production workflows. 

Key Features 

●       Live Caption Overlays for Content – Add real-time captions directly onto presentations, video streams, and other content.

●       Broadcast-Ready Output Formats – Supports lower / upper thirds, high-contrast captions, text overlays, and green screen compositing.

●       Production Workflow Integration – Works seamlessly with tools such as OBS, video switchers, and streaming platforms.

●       Fast Setup for Production Teams – Configure caption appearance and integrate into an existing workflow in seconds.

●       Reusable Caption Templates – Save caption styles and settings for consistent use across multiple events.

●       Professional Display Quality – Deliver clean captions suitable for main stage screens, livestreams, and recorded content. 

“Organizations are presenting more live content than ever,” Rathnam added. “From conferences and hybrid events to enterprise town halls and product launches, the Wordly Subtitles App makes it easy for production teams to embed captions directly on stage screens or into streams, creating accessible and professional experiences for all audiences.” 

How the Subtitles App Supports Enterprise Communications 

●       Improves accessibility by embedding real-time captions directly into presentations and broadcasts.

●       Ensures clarity for global teams during meetings, town halls, and corporate events.

●       Simplifies caption delivery for production teams by removing the need for side monitors or complex workflows.

●       Enhances hybrid events by helping both in-room and remote audiences follow presentations.

●       Delivers professional experiences with caption overlays designed for stage screens and livestreams. 

The launch of the Wordly Subtitles App is part of four major products introduced by Wordly this quarter, including Wordly Workspaces, mobile app extensions, and enhanced integration with Microsoft Teams. Together, these updates create a seamless ecosystem for real-time translation, captioning, and collaboration across desktop, mobile, internal meetings, and live event stages.

For more information about the Wordly Subtitles App go to: https://www.wordly.ai/ai-subtitle-generator.

SOUTH SAN FRANCISCO, Calif., March 11, 2026 — CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, provides an update through the letter to stockholders and stakeholders from CEO Chris Ehrlich:

To our stockholders and stakeholders:

Following our recent Form 8-K filing confirming receipt of convertible debt funding to support current operations, we believe it is an appropriate time to provide an update on CERo Therapeutics’ operational and scientific progress. Over the past six months, the Company has advanced its clinical development activities, engaged in strategic discussions, and continued to manage resources with fiscal discipline.

During this period, we have progressed the development of our lead candidate, CER-1236, including observations consistent with an acceptable safety and tolerability profile to date, across multiple treated patients. We have also observed biologic activity consistent with the mechanism of the therapy, including approximately 20–70-fold cell expansion, peaking between days 7–14 and followed by continued persistence as measured in peripheral blood. These early observations contribute to our understanding of CER-1236 and support continued clinical evaluation of the program.

Notably, in the second patient treated in our ongoing Phase I study, we observed an interval of apparent disease stability during which the patient’s disease progression and requirement for platelet transfusion support did not increase following multiple infusions of CER-1236. While this is an early observation from a single patient and Phase I studies are primarily designed to evaluate safety, we believe the clinical course of this patient is noteworthy.  This patient had previously been diagnosed with myelodysplastic syndrome (MDS), a disorder of the bone marrow that can progress to acute myeloid leukemia (AML).

The emerging clinical observations provide an early signal that supports continued investigation of CER-1236. These data are helping guide the Company’s ongoing development strategy, including exploration of dosing approaches and patient selection in future cohorts.

While CER-1236 demonstrated activity across multiple tumor models during preclinical development, the observations to date in the MDS setting highlight a potentially important area for further study. We believe these early findings may also support future discussions with potential strategic partners regarding the continued development of the program.

Progress in Phase 1 Clinical Trial and Strategic Focus on MDS
We recently announced data from our ongoing CERTAIN-T Phase 1 clinical trial that reflects the Company’s current development approach for our lead compound, CER-1236. Based in part on early clinical observations in a patient with MDS, a disorder of the bone marrow that can precede AML, the Company has refined its development strategy to increase focus on enrolling patients with MDS while maintaining optionality in AML.

This strategic refinement was informed in part by observations from a patient who received four infusions of CER-1236 over approximately five months at the lowest dose level in the study.

As previously announced, prior to receiving CER-1236 the patient required frequent platelet transfusions. During the period following treatment in the study, the patient experienced an interval of platelet transfusion independence lasting more than two months, exceeding the commonly referenced ≥56-day durability benchmark used in MDS studies.

The Company is actively seeking to enroll additional patients with similar clinical characteristics to further evaluate this observation. If similar findings are observed in additional patients, these data may help inform future discussions with regulatory authorities and potential strategic partners regarding the continued development of CER-1236.

To date, the Company has initiated the second cohort of the trial, and two additional patients have recently undergone apheresis, a procedure in which blood cells are collected to manufacture CER-1236 for each individual patient. The Company plans to initiate dosing for these patients during March and April.

Pursuing a Strategy to List on a Major Exchange
Re-establishing our listing on a major exchange remains one of our key priorities.  To that end, we have engaged with an investment bank to raise capital and pursue a strategy intended to support a potential relisting on the Nasdaq Capital Market.  We believe that our new partner’s institutional relationships and sector expertise align well with our goal of raising sufficient capital in a disciplined manner while attracting longer-term, knowledgeable investors who are familiar with the clinical development landscape and strategic direction. In addition, we are considering other potential paths for relisting on a national securities exchange, including potential business combinations with listed companies, which may include a reverse merger or a business combination with a special purpose acquisition company.

Continued Funding Support
As recently disclosed, as we pursue new financing opportunities and seek to relist on Nasdaq, our lead investor continues to support CERo’s operations through investments in convertible debt. Their commitment to CERo has enabled us  to sustain operations and advance our clinical programs. We believe our clinical development and focus on our financing efforts and strategy for relisting on Nasdaq will be beneficial to all CERo stockholders and are grateful for the continued confidence our loyal stockholder base.

Strategic Discussions Regarding Early Data Readouts
We continue to engage in ongoing discussions with potential strategic partners following the most recent data readouts, as is regularly seen in the biotech industry. While these  conversations are encouraging, they remain at an early stage and have not resulted in formal agreements. We believe the evolution of our strategy and growing dataset may catalyze future conversations. To the extent permitted under applicable law and contractual obligations, we expect to provide further updates to stockholders should any of these discussions advance in a manner that materially impacts the Company.

Board Expansion – Appointment of Eric Francois
Finally, we recently announced that Eric Francois joined our board of directors.  Eric brings decades of experience in life sciences finance, capital markets, and corporate development, including deep expertise in capital raising, M&A, and strategic partnerships.  His involvement with the Company is among multiple catalysts that, we believe, will positively impact CERo in the months to come.  Eric was instrumental in our discussions with our new investment bank and is already assisting with other potential funding opportunities, operational improvements, and external viewpoints on the Company’s next phase of growth.

Dedicated, Engaged Professionals Working Together to Achieve Success
It should never go without saying that CERo’s world class team – employees, partners, consultants, and advisors – all remain focused and excited about achieving the common goal of improved patient care and improving patients’ lives through innovative clinical development.  Despite challenges that might have derailed other companies several times over, the CERo team has continued to perform with enthusiasm toward the achievement of bringing CER-1236 to the next inflection point and beyond.

Our take-home message is clear:  CERo is operational, continuing to advance our clinical programs, and generally building momentum. We are committed to transparent communication, and we look forward to sharing the outcomes of each of our ongoing activities in the future. We thank you for your continued support and confidence in our novel approach to treatment and our leadership.

Sincerely,
Chris Ehrlich
CEO
CERo Therapeutics

Company extends its consumer-first foundation beyond fitness equipment e-commerce into the design and deployment of AI-powered robotics and intelligent consumer technologies

Sydney, Australia, March 11, 2026 — In a move that redefines its corporate identity and market trajectory, Fitell Corporation (NASDAQ: FTEL) (“Fitell”, “GMEX Robotics” or the “Company”) today announces its rebranding to GMEX Robotics. The rebrand reflects a deliberate strategic evolution of the Company’s mission, extending its consumer-first foundation beyond fitness equipment e-commerce into the design and deployment of AI-powered robotics and intelligent consumer technologies.

“This rebrand is a revolution in our ambition, but an evolution of our expertise,” said Sam Lu, GMEX Robotics CEO. “As Fitell, we built a robust operation centered on consumer needs. As GMEX Robotics, we amplify that focus by applying advanced artificial intelligence and robotics to solve real human problems. Our fitness and health division remains a vital part of our operations; it is our testing ground and our inspiration. It ensures that as we build sophisticated robots, we never lose sight of the human they are designed to serve.”

The Company filed its amended and restated memorandum and articles of association in accordance with the BVI Business Companies Act (as amended) and, effective March 2, 2026, completed its legal name change to “GMEX ROBOTICS CORPORATION ” pursuant to such filing (the “Name Change“). In connection with the Name Change, the Company will also change its ticker symbol on the Nasdaq Capital Market (the “Nasdaq”) from “FTEL” to “GMEX” (the “Ticker Change“).

The Company’s Class A ordinary shares (“Ordinary Shares“) are expected to commence trading on the Nasdaq under the new corporate name and new ticker symbol as early as market open on March 12th, 2026. In connection with the name and ticker changes, the Company’s CUSIP number will remain unchanged. No action is required by existing shareholders, nor will any certificates representing Ordinary Shares need to be exchanged.

The rebrand reflects the next phase of the company’s long-term vision. Effective immediately, GMEX Robotics will focus on designing, manufacturing, and commercializing AI-driven robotic solutions for the consumer market, building on its foundation of expertise in fitness and health products. This shift represents the Company’s commitment to leading the next technological wave, where intelligent machines become an integral part of daily life. Rather than a wholesale departure from its roots, GMEX Robotics will continue to operate its existing fitness and health-related product business, which remains the crucial operational foundation for future growth. This legacy vertical functions as a hands-on laboratory for understanding human movement, ergonomics, and daily routines. The deep understanding of consumer wellness garnered through years of serving the fitness market will directly inform the design and development of the Company’s next generation robotic products.

GMEX Robotics will focus its efforts on three primary pillars:

1. Consumer and Commercial Robotics: Developing intuitive and interactive robots designed to assist with daily tasks, provide smart home integration, and offer new levels of convenience and connectivity to boost productivity.
2. AI-Driven Hardware: Embedding advanced artificial intelligence into physical products to create self-learning and adaptive user experiences.
3. Innovation & Ecosystem: Building a robust ecosystem of robotic products that communicate and evolve, powered by proprietary AI algorithms.

While the Company’s history in the fitness sector provides a strong foundation in logistics, supply chain management, and consumer engagement, GMEX Robotics is now engineered for a different market. The Company is actively assembling a new leadership team and technical workforce specializing in mechatronics, computer vision, and machine learning to drive this ambitious agenda.

The transition from Fitell to GMEX Robotics signifies the close of one chapter and the exciting, bold beginning of another. The Company invites investors, innovators, and consumers to join them as they build the intelligent future.

Chennai, Mar 11th: Mr. M.P. Ahammad, Chairman, Malabar Group, has been honoured with the prestigious Business Bhushan Award at the Lokmat Maharashtrian of the Year Awards 2026, in recognition of his visionary leadership and pivotal role in transforming the global jewelleryretail landscape and society at large.

Held at the iconic Gateway of India, the awards ceremony brought together leading policymakers, industry leaders, and prominent personalities from business and entertainment. The event was attended by the Chief Minister, Sri. Devendra Fadvanis, and Deputy Chief Minister, Sri. Eknath Shinde of Maharashtra, Sri. Vijay Darda, Chairman of Lokmat alongside ministers, bureaucrats, and distinguished figures from across sectors.

Presented by Lokmat Media Group, the awards celebrate individuals whose vision, leadership, and achievements have significantly shaped industries while contributing meaningfully to society. Mr. Ahammad’s recognition highlights his remarkable entrepreneurial journey and the role he has played in building Malabar Gold & to become the 5th largest global jewellery retailer and the largest jewellery retailer of Indian origin.

Expressing his gratitude on receiving the honour, Mr. M.P. Ahammad, Chairman, Malabar Group, said, “I am deeply honoured to receive the Business Bhushan award at the LokmatMaharashtrian of the Year Awards. This recognition reflects the collective dedication of the entire Malabar family and the trust our customers have placed in us over the years. Our journey is founded on the principle of collective growth of all our stakeholders guided by responsibility, integrity, and a commitment to creating lasting value for society while continuing to pursue excellence in everything we do.” 

Founded in 1993, Malabar Gold & Diamonds has been a pioneer in fostering responsible and transparent jewellery retail, contributing significantly to employment generation, strengthening the organised retail ecosystem, and enhancing customer experience through access to world‑class designs and services.

Today, the brand stands as a true flag bearer of India, showcasing the nation’s craft and soul to the world through its 425 showrooms across 14 countries. The brand has reimagined the jewellery industry by integrating the entire value chain, from design and manufacturing to retail and beyond.

Maharashtra remains a key market for Malabar Gold & Diamonds, now with 34 showrooms across major cities. This growth has boosted employment, strengthened the organised jewellery ecosystem, and improved access to quality designs. His substantial contribution to the state earned him this honour, and the Group is committed to further expansion, targeting 64 stores in Maharashtra by 2029.

Beyond business growth, Mr. Ahammad advanced a purpose‑driven model by embedding CSR/ESG commitments into the company since inception, consistently contributing 5% of profits to education, healthcare, housing support and women’s empowerment programmes, benefiting the society across regions of operations.

His recognition with the Business Bhushan Award further reinforces his stature as one of India’s most respected business leaders whose entrepreneurial vision and values-driven leadership serve as an inspiration and a blueprint for collective progress for future global enterprises.

Mar 11: 0101.Today, a leading data-driven conversion specialist, has announced the appointment of Nitika Khanna as Director – Martech. In her new role, Khanna will spearhead the design and implementation of lifecycle-driven Martech architectures that integrate customer data, analytics, automation platforms, and communication systems into unified engagement ecosystems aimed at improving conversion, retention, and long-term customer value.

 With over a decade of experience across global consumer technology platforms, digital marketplaces, and enterprise consulting, Khanna brings deep expertise in building and scaling CRM, retention, and lifecycle engagement systems. Prior to joining 0101.Today, she held leadership roles including Director – Martech at Performics India, Head of CRM at MAISON D’AURAINE, Retention Consultant at WebEngage, and Head of CRM at Trell. She has also contributed to major CRM initiatives at Nykaa, designing retention frameworks, behavioural segmentation models, and automation systems for multiple markets.

Commenting on the appointment, Ajay Verma, Co-Founder and Managing Partner, 0101.Today, said:

“We are delighted to welcome Nitika to 0101.Today. Her deep understanding of Martech ecosystems and lifecycle engagement will play an important role as we continue helping enterprises translate customer data into measurable business outcomes and build integrated growth systems.”

Nitika Khanna, Director – Martech, 0101.Today, added:

“I’m excited to join 0101.Today at a time when organisations are looking to unlock greater value from their Martech investments. When data, technology and lifecycle strategies work together, businesses can create far more meaningful and consistent customer engagement. I look forward to helping enterprises build systems that translate customer data into measurable growth.”

Khanna’s appointment reinforces 0101.Today’s commitment to helping enterprises build integrated Martech infrastructures that transform customer data into actionable engagement frameworks, improve conversions, and drive sustainable growth.

 Rahul Singh, Chief Investment Officer Equities, Tata Asset Management

“Recent geopolitical developments in the Middle East have led to an increase in the risk premium for Indian equities, largely driven by concerns around crude prices and their potential impact on the rupee. However, valuations have become more reasonable with the Nifty trading around 20 times earnings. While near-term sentiment may remain sensitive to global developments, sectors such as consumer and pharmaceuticals could remain relatively insulated, while metals and energy may benefit from higher commodity prices. Credit growth has also improved to around 14.5 percent, which could support banking sector growth. Overall, earnings growth for the Nifty50 is expected to remain healthy at around 15–17 percent over FY26–FY27.”